This protocol lets us investigate drug-eluting stents in a small animal model of laryngotracheal stenosis letting us leverage genetically modified animals in a cost effective manner. Transoral placement of the drug-eluting airway stent spares the
이 콘텐츠에 액세스하려면 로그인하거나 무료 평가판을 시작하세요
Laryngotracheal stenosis results from pathologic scar deposition that critically narrows the tracheal airway and lacks effective medical therapies. Using a PLLA-PCL (70% poly-L-lactide and 30% polycaprolactone) stent as a local drug delivery system, potential therapies aimed at decreasing scar proliferation in the trachea can be studied.